Loading...
•
Sep 30, 2022
Sutro Q3 2022 Earnings Report
Reported third quarter financial results and business highlights.
Key Takeaways
Sutro Biopharma reported revenue of $25.1 million for the quarter ended September 30, 2022, and had cash, cash equivalents and marketable securities of $287.3 million as of September 30, 2022. The company's cash runway is projected into the first half of 2024.
STRO-002 data demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML are accepted for oral presentation at ASH 2022
STRO-002 data from the Phase 1 ovarian cancer dose-expansion cohort and the trial design of the Phase 2 registrational-enabling study will be reported by end of 2022
Vaxcyte reported positive topline data from its Phase 1/2 proof-of-concept study of VAX-24; Sutro is eligible to receive 4% royalties on worldwide net sales of VAX-24 and any licensed vaccine candidates, under an existing license agreement
Cash, cash equivalents and marketable securities totaled $287.3 million as of September 30, 2022, providing a projected cash runway into the first half of 2024 based on current business plans and assumptions
Sutro
Sutro
Forward Guidance
Sutro expects to report additional data on efficacy, safety, and durability from the Phase 1 dose-expansion cohort in patients with advanced ovarian cancer, together with the design of a registration-enabling Phase 2 study, by the end of 2022.